Viral suppression off ART using dual bNAb therapy

So far 65 out of 72 participants have been enrolled into the RIO study, we are close to finishing! We are still open and recruiting, if you think you may be able to join the study, please do get in touch.

The RIO study is looking at whether a new type of treatment can keep viral load undetectable without ART. This will involve asking all participants to stop ART for a short time.

The study will measure how long viral load stays undetectable without ART. It will also look at what happens to the HIV virus and immune system in blood samples. When virus becomes detectable in a blood test (viral rebound) you will be asked to re-start your ART.

RIO Trial interview with a participant

A RIO Trial participant kindly agreed to sit down with the RIO Trial Chief Investigator, Prof. Sarah Fidler. In the interview they give a firsthand account of their experiences taking part in the trial and their feelings about pausing antiretroviral therapy (ART) as part of the trial.

Working on the RIO Trial

In this video we hear from two members of the RIO Trial team in Brighton, Dr Mindy Clarke and Research Nurse, C Cable. They talk about their experiences working on the trial which asks participants to pause their antiretroviral therapy (ART) and regularly attend their clinic for viral load tests. Participants are followed up regularly to monitor the effect of stopping ART on the viral load after receiving an infusion of the study drug. Once the virus returns participants restart their ART and are again followed up regularly until undetectable again.

RIO trial interview with Clinical Research Nurse

In this video we see Prof Sarah Fidler interview Clinical Research Nurse, Ms Louise Terry working on the RIO trial. Here she talks about motivated participants who are willing to fit in a multitude of clinic visits and the overall experience being part of a cutting edge clinical trial.

Latest News

RIO is funded by the Bill & Melinda Gates Foundation. Imperial College London is the Trial Sponsor and the trial is coordinated by Imperial College London, The University of Oxford and The Rockefeller University.

Imperial College London logo
Oxford University logo
Rockefeller University logo
Bill and Melinda Gates Foundation logo